Mr. Newell has over 10 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc, where he ultimately served as Senior Vice President, Corporate and Business Development prior to Celera Genomics’s acquisition of Axys. For the 15 years prior to joining Axys, Mr. Newell practiced law at the law firm of Bingham McCutchen LLP.

Jay Shukert has been a consulting Chief Financial Officer to medical device and biotechnology companies for more than 15 years. His work focuses on companies in the development and early commercialization phases. His clients have included Millennium Pharmaceuticals, IDUN Pharmaceuticals, Prograft Medical, Coalescent Surgical, and Appriva Medical. Previous to his work as a consulting CFO, Jay was Vice President, Finance at CV Therapeutics and Controller at Neurex Corporation. Prior to those, he held various financial positions at Genentech and was a manager in the consulting practice at Arthur Andersen & Co. Mr. Shukert received an MBA from the University of California, Berkeley and a BS from the University of Pennsylvania.

Mr. Heinsohn has over 24 years of process development and manufacturing experience related to recombinant protein production. He came to Sutro after working at Genentech for 17 years, where he held the role of Senior Scientist and Senior Group Leader for process development, early stage purification activities. While at Genentech, he developed large-scale protein recovery processes, supported research and development activities and participated in regulatory filings for VEGF, thrombopoeitin, Lucentis, and other novel protein therapeutics. He was CMC team leader for the development and launch of Avastin. Prior to joining Genentech, Henry was employed by Genencor International where he was Senior Scientist. Previously, he was a scientist at Corning Medical and Scientific. Henry received a B.S. in Chemistry from North Carolina State University, and conducted postgraduate studies in Biochemistry at the Boston University.

Dr. Stolz has 15 years of business development experience working for companies that are both technology platform and therapeutics focused. She joins the company from Sunesis Pharmaceuticals where she was Vice President Corporate & Business Development. Prior to Sunesis, she served as Senior Director, Business Development for Aerovance, Inc. where she led efforts to partner the company’s Phase 2 asset for uncontrolled asthma. Lesley was Senior Director, Business Development for GPC Biotech AG of Germany from 2002 to 2006. She also served as Director, Business Development for Cell Genesys, Inc.. Dr. Stolz received her Ph.D. and M.S. degrees from the University of Rochester and a B.S. from the University of Virginia. She conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.

Dr. Christopher Murray is the Vice President of Research at Sutro Biopharma, Inc. Since joining Sutro in 2008, Dr. Murray has led the company’s engineering work on antibodies and other challenging proteins. With his coworkers, Dr. Murray has developed several novel technologies that unlock scalable cell-free synthesis of antibodies and other proteins. Prior to Sutro, Dr. Murray was an Associate Director of Molecular Biology at Catalyst Biosciences, Senior Staff Scientist in Protein Engineering at Applied Biosystems, and Senior Scientist at Genencor (1994-2004), where he developed and tested novel methods for targeted selections of biomolecules. He began his work in the field of protein engineering as an Assistant Professor of Chemistry at the University of Arkansas. Dr. Murray holds a Ph.D. in Organic Chemistry from the University of California, Santa Cruz.